Biosimilars

During the virtual European Society for Medical Oncology Congress 2021, 5-year follow-­up data from a clinial trial showed comparable results related to cardiac safety and long-term efficacy between trastuzumab (Herceptin) and the biosimilar trastuzumab-dttb (SB3; Ontruzant) in patients with HER2-positive, early or locally advanced breast cancer. These findings were reported in a poster presentation by Xavier Pivot, MD, PhD, General Director, Centre Paul Strauss, Institut de Cancérologie Strasbourg Europe, France, and colleagues. Read More ›

The advent of biologic drugs has had a significant impact on the management of patients with cancer. However, the high costs associated with these agents can hinder treatment access for many patients and place a significant burden on healthcare systems. As several biologics have come off patent over the past few years and more are expected to do so in the near future, biosimilars are poised to play an increasingly important role in reducing healthcare costs. Read More ›

Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. At the ASCO 2021 virtual annual meeting, Lalan S. Wilfong, MD, Executive Vice President, Value-Based Care and Quality Programs, and Medical Oncologist/Hematologist, Texas Oncology, Presbyterian Cancer Center Dallas, TX, discussed how a community practice model for therapeutic interchange of brand drugs to biosimilars led to a significant increase in utilization of biosimilars and substantial cost-savings over the course of a single year at his institution. Read More ›

As biosimilars are being used more and more in cancer treatment, it is increasingly important that navigators and financial advocates be familiar not only with how they work but also how patients with cancer should go about paying for them, according to Angie Santiago, AA, CRCS-I, lead financial advocate at the Sidney Kimmel Cancer Center/Jefferson Health. Read More ›

Although the role of biosimilars in the treatment of patients with cancer has been under review by payers and providers for several years, there remains conflicting application regarding policy and strategy. There is a growing need for discussions on biosimilars in the context of the current landscape, utilization and evidence, impact on costs of care, quality and payment reform, and potential policy and strategy solutions. Read More ›


The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab. Read More ›

Real-world national commercial administrative data showed that treatment adherence to infliximab biosimilar is high among patients who were infliximab-naïve, as well as those who had long exposure to infliximab. Read More ›

The findings of an online, cross-sectional survey indicate oncologists were less likely to prescribe biosimilars if their practice could lose money and control of the drug, despite clinical safety and efficacy between the biosimilar and originator. Read More ›

Real-world data indicate treatment adherence was highest among patients who had prior infliximab exposure but no prior infliximab biosimilar use. Read More ›

Page 1 of 4

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: